CGRB - CB7630 (Abiraterone Acetate) started phase 3 trial in chemotherapy-naive castration-resistant prostate cancer patients. <a href="http://finance.yahoo.com/news/Cougar-Biotechnology-bw-15066718.html?.v=1" rel="nofollow" target="_blank">http://finance.yahoo.com/news/Cougar-Biotechnology-bw-15066718.html?.v=1</a>